title: A fully integrated protein crystallization platform for small-molecule drug discovery.
abstract: Structure-based drug discovery in the pharmaceutical industry benefits from cost-efficient methodologies that quickly assess the feasibility of specific, often refractory, protein targets to form well-diffracting crystals. By tightly coupling construct and purification diversity with nanovolume crystallization, the Structural Biology Group at Syrrx has developed such a platform to support its small-molecule drug-discovery program. During the past 18 months of operation at Syrrx, the Structural Biology Group has executed several million crystallization and imaging trials on over 400 unique drug-discovery targets. Here, key components of the platform, as well as an analysis of some experimental results that allowed for platform optimization, will be described.
authors.affiliation: Syrrx, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA.
authors.forename: David
authors.initials: D
authors.lastname: Hosfield
authors.forename: John
authors.initials: J
authors.lastname: Palan
authors.forename: Mark
authors.initials: M
authors.lastname: Hilgers
authors.forename: Daniel
authors.initials: D
authors.lastname: Scheibe
authors.forename: Duncan E
authors.initials: DE
authors.lastname: McRee
authors.forename: Raymond C
authors.initials: RC
authors.lastname: Stevens
mesh_terms: D003001:Cloning, Molecular; D003460:Crystallization / Q000379:methods*; D015195:Drug Design; D014176:Protein Biosynthesis; D011506:Proteins / Q000737:chemistry* / Q000302:isolation & purification; D012371:Robotics
chemical_list: D011506:Proteins